Want to see ADCT full AI Analyst Report?
ADCT Stock Chart & Stats
$1.05
>-$0.01(-0.87%)
At close: 4:00 PM EDT
$1.05
>-$0.01(-0.87%)
Day’s Range― - ―
52-Week Range$0.78 - $4.98
Previous Close$1.19
Volume787.75K
Average Volume (3M)1.64M
Market Cap
$190.22M
Enterprise Value$64.32M
Total Cash (Recent Filing)$219.11M
Total Debt (Recent Filing)$417.11M
Price to Earnings (P/E)―
Beta2.56
Next Earnings
Nov 10, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding127,667,694
10 Day Avg. Volume2,286,212
30 Day Avg. Volume1,640,796
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)-2.41
Price to Sales (P/S)5.51
P/FCF Ratio-3.17
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue0.82
Enterprise Value/Gross Profit0.92
Enterprise Value/Ebitda-0.73
Forecast
1Y Price Target
$3.50Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.76
Revenue Forecast (FY)$79.53M
Bulls Say, Bears Say
Bulls Say
Revenue Rebound And Strong Gross MarginsImproving sales alongside consistently high gross margins indicates strong product-level economics and growing commercial traction. If this revenue base continues expanding, the company should have greater capacity to fund development and absorb fixed costs, supporting a more durable path toward operating leverage.
Lower Operating Expenses And Narrower LossesThe substantial reduction in operating expenses and net losses shows meaningful progress in financial discipline, not merely revenue growth. Continued cost control can extend available resources, reduce the cash required to support clinical programs, and improve the company’s ability to scale its commercial platform.
Restructuring Improves Financing FlexibilityThe restructuring directly addresses financial flexibility by adding capital, reducing outstanding principal, and easing scheduled repayment and covenant pressure. A longer runway gives ADC Therapeutics more time to fund Phase 3 studies, pursue regulatory opportunities, and develop ZYNLONTA without immediate refinancing needs.
Bears Say
Negative Equity And Elevated LeverageNegative equity reflects accumulated losses that have materially eroded the capital base, while debt exceeds the asset base. This weak balance-sheet position limits financial flexibility, increases dependence on external financing, and leaves the company more exposed if development or commercial plans require additional capital.
Persistent Cash Burn And Deep LossesThe company is still converting reported losses into substantial cash outflows, so improving revenue has not yet produced self-sustaining operations. Persistent burn can consume capital needed for clinical development and commercialization, making long-term execution increasingly dependent on cost reductions, financing, or future product growth.
FDA Benefit-risk And Infection ConcernsRegulatory and safety concerns create a durable obstacle to using LOTIS-5 as a straightforward route to full approval or broader use. Additional data, risk-management measures, or pathway changes may be required, potentially delaying label expansion, compendia adoption, and the commercial value of ZYNLONTA.
ADC Therapeutics News
ADCT FAQ
What was ADC Therapeutics Ltd’s price range in the past 12 months?
ADC Therapeutics Ltd lowest stock price was $0.78 and its highest was $4.98 in the past 12 months.
What is ADC Therapeutics Ltd’s market cap?
ADC Therapeutics Ltd’s market cap is $190.22M.
When is ADC Therapeutics Ltd’s upcoming earnings report date?
ADC Therapeutics Ltd’s upcoming earnings report date is Nov 10, 2026 which is in 23 days.
How were ADC Therapeutics Ltd’s earnings last quarter?
ADC Therapeutics Ltd released its earnings results on Aug 13, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.216 by $0.106.
Is ADC Therapeutics Ltd overvalued?
According to Wall Street analysts ADC Therapeutics Ltd’s price is currently Undervalued.
Does ADC Therapeutics Ltd pay dividends?
ADC Therapeutics Ltd does not currently pay dividends.
What is ADC Therapeutics Ltd’s EPS estimate?
ADC Therapeutics Ltd’s EPS estimate is -0.21.
How many shares outstanding does ADC Therapeutics Ltd have?
ADC Therapeutics Ltd has 127,667,694 shares outstanding.
What happened to ADC Therapeutics Ltd’s price movement after its last earnings report?
ADC Therapeutics Ltd reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.216. Following the earnings report the stock price went down -14.634%.
Which hedge fund is a major shareholder of ADC Therapeutics Ltd?
Currently, no hedge funds are holding shares in ADCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ADC Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.50 (233.33% Upside)
$3.50 (233.33% Upside)
Blogger Sentiment
Neutral
ADCT Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 431.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.10%
12-Months-Change
Fundamentals
Return on Equity
44.63%
Trailing 12-Months
Asset Growth
-13.12%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ADC Therapeutics Ltd
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
ADCT Company Deck
ADCT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: financially the company showed meaningful improvement with stable product revenues, reduced adjusted operating expenses (-22%) and a materially narrower GAAP net loss (from $56.6M to $16.6M), plus a healthy cash position and programmatic cost savings (~$10M annualized). Clinically, there are important positives — LOTIS-5 met its primary endpoint (PFS) and LOTIS-7 enrollment is complete with data the company characterizes as highly compelling. However, significant regulatory uncertainty remains because the FDA expressed substantial concerns about the LOTIS-5 benefit–risk profile and LOTIS-5 included fatal infection events (previously disclosed ~4%), creating risk to the path for full approval and timing of label/compendia actions. Operationally, cost of product sales increased materially (~188% QoQ year-over-year for the quarter) and the company recorded one-time reorganization costs tied to a ~17% headcount reduction. Given the balance of strong financial improvements and encouraging combination data versus meaningful regulatory and safety concerns, the overall tone is balanced but cautious.View all ADCT earnings summariesADCT Stock 12 Month Forecast
Average Price Target
$3.50
▲(233.33% Upside)
Technical Analysis
Cellectis SA
―
Black Diamond Therapeutics
―
Innate Pharma
―
Adagene
―
Xilio Therapeutics
―
Ownership Overview
22.63% Insiders
6.23% Mutual Funds
0.06% Other Institutional Investors
65.95% Public Companies and
Individual Investors